Aljazira Capital Reduces Jamjoom Pharmaceuticals PT, Keeps at Neutral

MT Newswires · 3d ago
08:36 AM EDT, 08/27/2026 (MT Newswires) -- Aljazira Capital Co. on Wednesday decreased the price target for pharmaceutical company Jamjoom Pharmaceuticals Factory (SASE:4015) to 144.90 Saudi riyals from 167.20 riyals, while maintaining its neutral rating. (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)